2026 Q1 -tulosraportti
81 päivää sitten
‧1 t 7 min
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 29.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 28.1. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenTEVA will release its earnings report on 29/7-26. Exciting test of the A-C line in a contracting triangle. Since the preliminary price peak on 3/2-26 at 37.35, I have closely followed the price from an Elliott Wave perspective, as Teva since the bottom at 7.09 on 31/5-23 has followed a clear Elliott Wave pattern. The peak on 3/2-26 marked the end of wave (3) of ((3)). After this comes a correction, wave (4) of ((3)). As far as I can see, that correction has been a contracting triangle, where waves A, B, C, D are clearly visible, and now the probably completed wave E, which likely ended with a bottom at 31.28. Over the last couple of days, an intensive test of the A-C line in the chart has taken place. But the line has held so far. Phase A-D at the top of the chart refers to Richard D. Wyckoff's methodology. If my interpretation is correct, and I can absolutely be wrong and have been before, then we are facing an upward impulse wave (5) of ((3)). And if my assumption is correct, then the minimum price target is 31.28 + 11.57 = 42.85 usd. But if the earnings report disappoints on 29/7, then we are in a completely different situation. Here are a couple of charts From the bottom at 7.09 to today: https://schrts.co/qKWZNfyf From Dec 2025 to today: https://schrts.co/ReCgqiZf During my summer vacation on lovely Anholt, I am re-reading "Elliott Wave Trading by Wayne Gorman and Jeffrey Kennedy". A must-read book for those who look to this chart methodology, which is unsurpassed in emotional markets. I am fully aware that TEVA, in a few years, from a purely fundamental-analytical perspective, will likely have an EPS of at least 5-6 usd.
·2 päivää sittenTeva wins reversal in migraine case which means that Eli Lilly must pay 176.5imio US dollar to Teva as the case stands now. https://www.fiercepharma.com/pharma/lilly-gets-reversal-against-teva-judge-overturns-176m-verdict
·7.7.Teva is holding a press conference today at 8.00 ET. The topic is a successful 1b study against Vitiligo (chronic disease with loss of skin pigments, which causes white patches on the body and face). The study is now in phase 2b.
So why does the share price dive after the announcement of a successful study and the next phase in the pipeline?- ·25.6.TEVA published on June 18 their Q2 2026 Aide Memoire before the upcoming financial report. For the curious, the most important is summarized here: 1. The Emalex acquisition is now closed Teva has completed the acquisition of Emalex Biosciences on June 10, 2026 for $700 million cash. It was previously accounted for as an assumption in the 2026 guidance, but now the transaction is actually closed. This also means that Teva expects a $700 million IPR&D expense in Q2, which will significantly impact Q2 earnings. 2. Ecopipam NDA has been submitted to the FDA The most concrete pipeline update is that Teva on June 18, 2026 has submitted an NDA to the FDA for ecopipam for the treatment of pediatric Tourette's syndrome. Ecopipam comes from the Emalex acquisition and has now officially been added to the pipeline overview. If approved and commercialized, Teva expects approx. 80% product-level gross margin and accretion to margins and non-GAAP EPS in 2028.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
81 päivää sitten
‧1 t 7 min
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenTEVA will release its earnings report on 29/7-26. Exciting test of the A-C line in a contracting triangle. Since the preliminary price peak on 3/2-26 at 37.35, I have closely followed the price from an Elliott Wave perspective, as Teva since the bottom at 7.09 on 31/5-23 has followed a clear Elliott Wave pattern. The peak on 3/2-26 marked the end of wave (3) of ((3)). After this comes a correction, wave (4) of ((3)). As far as I can see, that correction has been a contracting triangle, where waves A, B, C, D are clearly visible, and now the probably completed wave E, which likely ended with a bottom at 31.28. Over the last couple of days, an intensive test of the A-C line in the chart has taken place. But the line has held so far. Phase A-D at the top of the chart refers to Richard D. Wyckoff's methodology. If my interpretation is correct, and I can absolutely be wrong and have been before, then we are facing an upward impulse wave (5) of ((3)). And if my assumption is correct, then the minimum price target is 31.28 + 11.57 = 42.85 usd. But if the earnings report disappoints on 29/7, then we are in a completely different situation. Here are a couple of charts From the bottom at 7.09 to today: https://schrts.co/qKWZNfyf From Dec 2025 to today: https://schrts.co/ReCgqiZf During my summer vacation on lovely Anholt, I am re-reading "Elliott Wave Trading by Wayne Gorman and Jeffrey Kennedy". A must-read book for those who look to this chart methodology, which is unsurpassed in emotional markets. I am fully aware that TEVA, in a few years, from a purely fundamental-analytical perspective, will likely have an EPS of at least 5-6 usd.
- ·2 päivää sittenTeva wins reversal in migraine case which means that Eli Lilly must pay 176.5imio US dollar to Teva as the case stands now. https://www.fiercepharma.com/pharma/lilly-gets-reversal-against-teva-judge-overturns-176m-verdict
- ·7.7.Teva is holding a press conference today at 8.00 ET. The topic is a successful 1b study against Vitiligo (chronic disease with loss of skin pigments, which causes white patches on the body and face). The study is now in phase 2b.So why does the share price dive after the announcement of a successful study and the next phase in the pipeline?
- ·25.6.TEVA published on June 18 their Q2 2026 Aide Memoire before the upcoming financial report. For the curious, the most important is summarized here: 1. The Emalex acquisition is now closed Teva has completed the acquisition of Emalex Biosciences on June 10, 2026 for $700 million cash. It was previously accounted for as an assumption in the 2026 guidance, but now the transaction is actually closed. This also means that Teva expects a $700 million IPR&D expense in Q2, which will significantly impact Q2 earnings. 2. Ecopipam NDA has been submitted to the FDA The most concrete pipeline update is that Teva on June 18, 2026 has submitted an NDA to the FDA for ecopipam for the treatment of pediatric Tourette's syndrome. Ecopipam comes from the Emalex acquisition and has now officially been added to the pipeline overview. If approved and commercialized, Teva expects approx. 80% product-level gross margin and accretion to margins and non-GAAP EPS in 2028.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 29.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 28.1. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
2026 Q1 -tulosraportti
81 päivää sitten
‧1 t 7 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 29.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 28.1. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenTEVA will release its earnings report on 29/7-26. Exciting test of the A-C line in a contracting triangle. Since the preliminary price peak on 3/2-26 at 37.35, I have closely followed the price from an Elliott Wave perspective, as Teva since the bottom at 7.09 on 31/5-23 has followed a clear Elliott Wave pattern. The peak on 3/2-26 marked the end of wave (3) of ((3)). After this comes a correction, wave (4) of ((3)). As far as I can see, that correction has been a contracting triangle, where waves A, B, C, D are clearly visible, and now the probably completed wave E, which likely ended with a bottom at 31.28. Over the last couple of days, an intensive test of the A-C line in the chart has taken place. But the line has held so far. Phase A-D at the top of the chart refers to Richard D. Wyckoff's methodology. If my interpretation is correct, and I can absolutely be wrong and have been before, then we are facing an upward impulse wave (5) of ((3)). And if my assumption is correct, then the minimum price target is 31.28 + 11.57 = 42.85 usd. But if the earnings report disappoints on 29/7, then we are in a completely different situation. Here are a couple of charts From the bottom at 7.09 to today: https://schrts.co/qKWZNfyf From Dec 2025 to today: https://schrts.co/ReCgqiZf During my summer vacation on lovely Anholt, I am re-reading "Elliott Wave Trading by Wayne Gorman and Jeffrey Kennedy". A must-read book for those who look to this chart methodology, which is unsurpassed in emotional markets. I am fully aware that TEVA, in a few years, from a purely fundamental-analytical perspective, will likely have an EPS of at least 5-6 usd.
- ·2 päivää sittenTeva wins reversal in migraine case which means that Eli Lilly must pay 176.5imio US dollar to Teva as the case stands now. https://www.fiercepharma.com/pharma/lilly-gets-reversal-against-teva-judge-overturns-176m-verdict
- ·7.7.Teva is holding a press conference today at 8.00 ET. The topic is a successful 1b study against Vitiligo (chronic disease with loss of skin pigments, which causes white patches on the body and face). The study is now in phase 2b.So why does the share price dive after the announcement of a successful study and the next phase in the pipeline?
- ·25.6.TEVA published on June 18 their Q2 2026 Aide Memoire before the upcoming financial report. For the curious, the most important is summarized here: 1. The Emalex acquisition is now closed Teva has completed the acquisition of Emalex Biosciences on June 10, 2026 for $700 million cash. It was previously accounted for as an assumption in the 2026 guidance, but now the transaction is actually closed. This also means that Teva expects a $700 million IPR&D expense in Q2, which will significantly impact Q2 earnings. 2. Ecopipam NDA has been submitted to the FDA The most concrete pipeline update is that Teva on June 18, 2026 has submitted an NDA to the FDA for ecopipam for the treatment of pediatric Tourette's syndrome. Ecopipam comes from the Emalex acquisition and has now officially been added to the pipeline overview. If approved and commercialized, Teva expects approx. 80% product-level gross margin and accretion to margins and non-GAAP EPS in 2028.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt